Short answer
Cytek Biosciences, Inc. (CTKB) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $44M (up 6.5% year over year) with net income of −$19M.
Q1 2026 key financials · XBRL
- Revenue
- $44M
- +6.5% YoY
- Net income
- −$19M
- −65.5% YoY
- Operating margin
- -41.8%
- Gross margin
- 48.2%
Source: XBRL data from the Cytek Biosciences, Inc. (CTKB) Q1 2026 10-Q on SEC EDGAR. USD.
Cytek Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized trade risk, triggered by substantial new U.S. tariffs and potential retaliation, threatening component costs and international demand
- Most materially updated supply risk, with anticipated plastics shortages prompting longer-horizon orders and higher procurement costs
- Regulatory compliance exposure from expanding tariffs and trade restrictions, including potential civil or criminal enforcement
- Near-term performance risk from six-month-or-longer instrument sales cycles and quarterly revenue volatility
- Financial risk from foreign-currency exchange-rate fluctuations across significant international operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cytek Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.